Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact firstname.lastname@example.org.
Utility of SARS-CoV-2 Rapid Antigen Testing for Patient Triage in the Emergency Department: A Clinical Implementation Study in Melbourne, Australia
19 Pages Posted: 2 Feb 2022More...
Background: Early, rapid detection of SARS-CoV-2 is essential in healthcare settings in order to implement appropriate infection control precautions and rapidly assign patients to appropriate care pathways. Rapid testing methods, such as SARS-CoV-2 rapid antigen testing (RAT) may improve patient care, despite a lower sensitivity than real-time PCR (RT-PCR) testing.
Methods: Symptomatic patients presenting to an Emergency Department (ED) in Melbourne, Australia, were risk stratified for their likelihood of active COVID-19 infection, and tested by both Abbott Panbio™ COVID-12 Ag test and SARS-CoV-2 RT-PCR. Patients with a positive RAT in the ‘At or High Risk’ COVID-19 group were moved immediately to a COVID-19 ward rather than waiting for a RT-PCR result. Clinical and laboratory data were extracted to determine test performance characteristics and length of stay in the ED.
Findings: Analysis of 1762 paired RAT/RT-PCR samples demonstrated an overall sensitivity of 75.5% (95% CI: 69·9-80·4) for the Abbott Panbio™ COVID-12 Ag test, with specificity of 100% (95% CI: 99·8-100). Sensitivity improved with increasing risk for COVID-19 infection, from 72·4% (95% CI: 52·8-87·3) in the ‘No Risk’ cohort to 100% (95% CI: 29·2-100) in the ‘High Risk’ group. Time in the ED for the ‘At/High Risk’ group decreased from 421 minutes (IQR: 281, 525) to 274 minutes (140, 425), p = 0.02.
Interpretation: The positive predictive value of a positive RAT in this setting was high, allowing more rapid instigation of COVID-19 positive care pathways and an improvement in patient flow within the ED.
Funding Information: This work was funded by the Royal Melbourne Hospital, Melbourne, Australia.
Declaration of Interests: The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
Ethics Approval Statement: This study was approved as a quality assurance activity with Human Research Ethic Committee approval from the Royal Melbourne Hospital (QA2020085).
Keywords: SARS-CoV-2, Rapid antigen testing, Abbott Panbio, Emergency Department
Suggested Citation: Suggested Citation